Back

Sodium-glucose co-transporter 2 inhibitor empagliflozin inhibits the cardiac Na+/H+ exchanger 1: persistent inhibition under various experimental conditions

Cardiovascular Research

1 April 2021
Organised by: Logo
Read full article
ESC Journals

Contributors

Coert J Zuurbier
Coert J Zuurbier

Author

Antonius Baartscheer
Antonius Baartscheer

Author

Cees A Schumacher
Cees A Schumacher

Author

Jan W T Fiolet
Jan W T Fiolet

Author

Ruben Coronel
Ruben Coronel

Author

Amsterdam University Medical Centre (AUMC) Amsterdam , Netherlands (The)

You may be interested in
thumbnail
Congress Presentation
The effect of empagliflozin and dapagliflozin on the change of Na+-Li+-countertransport speed.
29 June 2021
thumbnail
Congress Session
Diabetes, obesity, and heart failure
19 May 2025
thumbnail
Congress Presentation
Empagliflozin inhibits increased Na influx in HFpEF cardiomyocytes and reduces arrhythmic activity in human atrial trabeculae
26 August 2022
thumbnail
Congress Presentation
Empagliflozin treatment does not affect the hypertensive response to Ang II administration to rats but decreases oxidative stress in the arterial wall, and endothelial and cardiac dysfunction
1 September 2020

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources